Illumina ordered to pay BGI subsidiary $333 million in DNA-sequencing patent case
Reuters
Published May 06, 2022 04:46PM ET
Updated May 06, 2022 07:05PM ET
By Blake Brittain
(Reuters) - A Delaware jury on Friday ordered Illumina Inc (NASDAQ:ILMN) to pay more than $333 million to a U.S. unit of Chinese genomics company BGI Group after finding that Illumina's DNA-sequencing systems infringed two patents.
The jury also said Illumina infringed the patents willfully, and that three patents it had accused BGI's Complete Genomics unit of infringing were invalid.
BGI and Illumina are both major providers of genome-analysis technology used to detect genetic diseases. The companies have been embroiled in a global legal battle over their respective sequencing technologies, with court cases in countries including Germany, Denmark, Switzerland, and Turkey.
Illumina's stock was down more than 14% Friday following the verdict.
Illumina previously won $8 million from BGI in a jury verdict in San Francisco and a ban on U.S. sales of some BGI products.
In the Delaware case, San Jose, California-based Complete Genomics Inc, a BGI subsidiary, had challenged Illumina's "two-channel" sequencing systems and kits to prepare DNA fragments for sequencing of violating its patent rights.
An Illumina spokesperson said the company plans to appeal and that the verdict should not affect its ability to supply its customers.
An attorney for Complete Genomics said the company was pleased with the award, which the judge could multiply based the jury's finding of willful infringement.
Illumina also said Friday in a filing with the U.S. Securities & Exchange Commission that it may have to pay interest and an ongoing royalty until the patents expire in 2029 if it loses on appeal.
(The story corrects statement in paragraph 1 that Complete Genomics is a subsidiary of BGI Genomics to reflect that it is part of BGI Group.)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.